Stereoisomers with high affinity for adrenergic receptors

Details Stereoisomers with high affinity for adrenergic receptors Stereoisomers with high affinity for adrenergic receptors

2007-06-19

2007-06-19

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S345000, C546S343000

Reexamination Certificate

active

10681915

ABSTRACT:
The present invention provides stereoscopically-pure diastereomers of Formula I:In a preferred embodiment, the stereoisomers of the present invention are of Formula II, depicted below:R2, R3and R4are independently H, OH, OCH3, CH2OH, NHCONH2, NH2, halogen or CF3, and R1is pyridine, or an amine which may be substituted with hydrogen, lower alkyl, lower alkylenearyl, lower alkylenephenyl, lower alkylenehydroxyphenyl, lower alkyleneamine, lower alkyleneaminoaryl, lower alkylaminohydroxyphenyl, or a similar functional group. R5is hydrogen, hydroxyl or methyl; R6is hydrogen, lower alkyl, lower alkylenaryl, lower alkylenephenyl, lower alkylenehydroxyphenyl, lower alkyleneamine, lower alkyleneaminoaryl, lower alkylaminohydroxyphenyl, and the like. For both Formula I and Formual II, the first carbon on the side chain progressing from the ring is preferably in the R-configuration. The second carbon atom on the side chain of Formula II, which is attached to R5, may or may not be a chiral center. However, when the second carbon atom is a chiral center, it is preferably in the S-configuration. The present invention contemplates each stereoisomer of Formula I and II in substantially-pure form.The present invention also provides methods of relieving nasal, sinus and bronchial congestion and of treating attention deficit hyperactivity disorder and obesity. The present stereoisomers may also be used to induce pupil dilation. These methods include administering to a mammal a composition containing a therapeutically effective amount of a stereoscopically-pure stereoisomer of Formula I or II with a pharmaceutically acceptable excipient.

REFERENCES:
patent: 3644353 (1972-02-01), Lunts et al.
patent: 3885047 (1975-05-01), Seidehamel et al.
patent: 3985897 (1976-10-01), Seidehamel et al.
patent: 4695580 (1987-09-01), Ohashi et al.
patent: 4727078 (1988-02-01), Terao et al.
patent: 4853381 (1989-08-01), Finch et al.
patent: 4876436 (1989-10-01), Ide et al.
patent: 5248695 (1993-09-01), Resemann et al.
patent: 5292753 (1994-03-01), Resemann et al.
patent: 5362755 (1994-11-01), Barberich et al.
patent: 5380729 (1995-01-01), DeHaven-Hudkins et al.
patent: 5395957 (1995-03-01), Resemann et al.
patent: 5399765 (1995-03-01), Gao et al.
patent: 5442118 (1995-08-01), Gao et al.
patent: 5545745 (1996-08-01), Gao et al.
patent: 5547994 (1996-08-01), Barberich et al.
patent: 5648386 (1997-07-01), Resemann et al.
patent: 5708036 (1998-01-01), Pesterfield, Jr.
patent: 756973Q (1971-02-01), None
patent: 768120Q (1971-06-01), None
patent: 786261Q (1971-07-01), None
patent: 2065051 (1997-10-01), None
patent: 2400533 (1973-01-01), None
patent: 390762 (1989-03-01), None
patent: 455155 (1990-05-01), None
patent: 460924 (1991-03-01), None
patent: 0422889 (1991-04-01), None
patent: 4151935 (1978-05-01), None
patent: 0132935 (1983-12-01), None
patent: 1007238 (1984-06-01), None
patent: 1085197 (1984-10-01), None
patent: 2228298 (1986-03-01), None
patent: 7303612 (1973-09-01), None
patent: 7308193 (1973-12-01), None
patent: WO 9109596 (1990-01-01), None
patent: WO9318007 (1992-03-01), None
patent: WO9508529 (1993-09-01), None
patent: WO 9532178 (1995-01-01), None
patent: WO9730023 (1996-02-01), None
patent: WO 9726871 (1996-08-01), None
Corey, E. J. and Christopher J. Helal, “Asymmetric Synthesis of (S)-carbinoxamine, New Aspects of Oxazaborolidine-catalyzed Enantioselective Carbonyl Reduction,” Tetrahedron Letters (1996), 37 (32), pp. 5675-5678.
CAPLUS Accession No. 1990:98344, abstract of “Synthesis of some optically active alpha-pyridylcarbinols from the CD of their in situ complexes with Mo2(OAc)4,” (1989), Berova et al, vol. 62(2B), pp. 411-422.

Affiliated with

Also associated with

Rating

Stereoisomers with high affinity for adrenergic receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stereoisomers with high affinity for adrenergic receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stereoisomers with high affinity for adrenergic receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3869039